• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by OmniAb Inc.

    2/17/26 4:33:03 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001237556
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    OmniAb, Inc.
    SEC File Number
    001-40720
    Address of Issuer
    5980 HORTON STREET
    SUITE 600
    EMERYVILLE
    CALIFORNIA
    94608
    Phone
    510-250-7800
    Name of Person for Whose Account the Securities are To Be Sold
    FOEHR MATTHEW W
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES
    200 W CIVIC CENTER DR. 4TH FLOOR
    SANDY � UT � 84070
    2048334821.1014395540002/17/2026
    NASDAQ
    COMMON
    MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES
    200 W CIVIC CENTER DR. 4TH FLOOR
    SANDY � UT � 84070
    3045151766.7014395540002/18/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON02/16/2026RESTRICTED STOCKISSUERCheckbox not checked3645802/16/2026COMPENSATION
    COMMON02/18/2026RESTRICTED STOCKISSUERCheckbox not checked5833302/18/2026COMPENSATION

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Matthew W Foehr
    5980 HORTON STREET SUITE 600
    EMERYVILLE � CA � 94608
    COMMON12/08/20251366626798.27

    144: Remarks and Signature

    Remarks
    Represents the number of shares expected to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a sell-to-cover transaction and do not represent discretionary trades by the reporting person.
    Date of Notice
    02/17/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Charles S. Berkman, as Attorney-In-Fact for Matthew W. Foehr

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $OABI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on OmniAb with a new price target

    RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

    11/29/23 7:31:15 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    The Benchmark Company initiated coverage on OmniAb with a new price target

    The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

    4/21/23 7:43:22 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Craig Hallum initiated coverage on OmniAb with a new price target

    Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

    4/13/23 9:08:06 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Conference Call Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. "OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, several later-stage assets are emerging with potential to generate meaningful milestones and, ultimately, recurring royalty revenue," said Matt Foehr, Chief Executive Officer of Omn

    3/4/26 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Participate at the Leerink Partners Global Healthcare Conference

    OmniAb, Inc. (NASDAQ:OABI) today announced that management will participate at the Leerink Global Healthcare Conference taking place March 8-11, 2026, at the W South Beach in Miami. Management will present a corporate overview on Tuesday, March 10th at 3:40 p.m. Eastern time and will hold one-on-one meetings with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their Leerink Partners representative, or email [email protected]. About OmniAb® OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation th

    2/24/26 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

    OmniAb, Inc. (NASDAQ:OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quarter 2025 financial results and business updates       Date:   Wednesday, March 4, 2026       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549-8228    

    2/19/26 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Berkman Charles S converted options into 18,750 shares and sold $16,541 worth of shares (9,673 units at $1.71), increasing direct ownership by 2% to 392,700 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    2/18/26 6:36:13 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Executive VP, Finance and CFO Gustafson Kurt A converted options into 18,750 shares and sold $15,905 worth of shares (9,301 units at $1.71), increasing direct ownership by 4% to 268,851 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    2/18/26 6:35:30 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    President and CEO Foehr Matthew W converted options into 58,333 shares and sold $52,742 worth of shares (30,843 units at $1.71), increasing direct ownership by 0.63% to 4,403,277 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    2/18/26 6:34:48 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Higgins John L bought $107,707 worth of shares (77,261 units at $1.39), increasing direct ownership by 3% to 2,929,148 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    11/10/25 8:30:36 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/15/25 4:02:17 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/14/25 5:04:09 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    SEC Filings

    View All

    SEC Form 10-K filed by OmniAb Inc.

    10-K - OmniAb, Inc. (0001846253) (Filer)

    3/4/26 4:40:43 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OmniAb, Inc. (0001846253) (Filer)

    3/4/26 4:13:27 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    2/17/26 4:33:03 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Leadership Updates

    Live Leadership Updates

    View All

    OmniAb Appoints Steve Love to its Board of Directors

    OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

    11/1/23 9:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Financials

    Live finance-specific insights

    View All

    OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Conference Call Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. "OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, several later-stage assets are emerging with potential to generate meaningful milestones and, ultimately, recurring royalty revenue," said Matt Foehr, Chief Executive Officer of Omn

    3/4/26 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

    OmniAb, Inc. (NASDAQ:OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quarter 2025 financial results and business updates       Date:   Wednesday, March 4, 2026       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549-8228    

    2/19/26 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

    First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

    12/15/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

    SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

    11/14/24 4:06:53 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

    SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

    7/2/24 5:00:16 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care